Clarity Pharmaceuticals (ASX:CU6) Interest Received : A$2.25 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Clarity Pharmaceuticals Interest Received?

Clarity Pharmaceuticals's Interest Received for the six months ended in Dec. 2023 was A$1.11 Mil.

Clarity Pharmaceuticals's Interest Received for the trailing twelve months (TTM) ended in Dec. 2023 was A$2.25 Mil.

Clarity Pharmaceuticals Interest Received Historical Data

The historical data trend for Clarity Pharmaceuticals's Interest Received can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals Interest Received Chart

Clarity Pharmaceuticals Annual Data

Trend

Jun22

Jun23

Interest Received

0.08

1.58

Clarity Pharmaceuticals Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Received	Get a 7-Day Free Trial			0.02	0.06	0.44	1.14	1.11

Clarity Pharmaceuticals Interest Received Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Interest Received represents interest received by the company in the direct cash flow method.

Interest Received for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$2.25 Mil.

Clarity Pharmaceuticals Interest Received Related Terms

Thank you for viewing the detailed overview of Clarity Pharmaceuticals's Interest Received provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarity Pharmaceuticals (ASX:CU6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (ASX:CU6) » Definitions » Interest Received

Comparable Companies

Traded in Other Exchanges

CLRPF:USA

Address

4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015

Website

https://www.claritypharmaceuticals.com

Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.

Clarity Pharmaceuticals (ASX:CU6) Headlines

No Headlines